A Practical Guide to Make Digital Tools Work With GLP-1s
GLP-1 receptor agonists have transformed obesity and type 2 diabetes treatment, but patients often struggle with adherence and management. Many turn to digital tools for support, yet their effectiveness varies significantly. Clinicians emphasize the importance of integrating these tools into care while focusing on meaningful health outcomes rather than superficial metrics.
- ▪65% of patients without type 2 diabetes discontinue GLP-1 therapy within a year, compared to 47% of those with type 2 diabetes.
- ▪Clinicians should prioritize real health outcomes over marketing claims when evaluating digital tools.
- ▪Apps that do not align with current metabolic health paradigms may reinforce unhealthy behaviors.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/practical-guide-make-digital-tools-work-glp-1s-2026a1000g4q?src=rss |
| Publication time | Tue, 19 May 2026 03:17:55 EDT |
| Retrieval time | 2026-05-19T07:34:57.437Z |
| Last seen | 2026-05-19T07:34:57.437Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | WjvmdjB0gKAt |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
GLP-1 receptor agonists have reshaped the treatment of obesity and type 2 diabetes, but the prescription is only the starting point. Patients face a steep learning curve around nutrition, side-effect management, and long-term behavior change, and many turn to apps, wearables, and telehealth platforms to fill the gaps between office visits.Real-world persistence tells a tougher story. A 2025 cohort study published in JAMA Network Open found that 65% of patients without type 2 diabetes discontinued GLP-1 therapy within a year compared with 47% among those with type 2 diabetes.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
